Literature DB >> 7908672

MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection.

A Karlsson1, K Parsmyr, E Sandström, E M Fenyö, J Albert.   

Abstract

The ability of human immunodeficiency virus type 1 (HIV-1) isolates to replicate in MT-2 cells was investigated as a prognostic marker for disease progression and CD4+ lymphocyte depletion in 53 HIV-1-infected, asymptomatic individuals. MT-2-negative viruses were isolated from 49% of the patients both early and late during the follow-up period; 38% converted from being MT-2 negative to MT-2 positive, while 11% were MT-2 positive throughout the study. One individual showed a fluctuating virus phenotype. The loss of CD4+ lymphocytes was significantly more rapid in MT-2-positive patients. We found a broad spectrum of CD4+ lymphocyte changes in patients whose virus changed its MT-2 tropism. Our data suggest that the changes could be divided into three general patterns. A stable or slowly decreasing CD4+ lymphocyte count changed into a more rapid fall in 44% of the patients, no significant change in rate of decline could be noted in 44% of the patients, while a stable CD4+ lymphocyte level after a change in MT-2 tropism was noted in 12% of the patients. A correlation between MT-2 tropism and clinical symptoms was also noted. Half of the patients with MT-2-negative virus throughout the study were still asymptomatic after a mean follow-up time of 80 months, while only 15% of those who converted remained asymptomatic. All patients with MT-2-positive viruses at the time of inclusion in the study developed HIV-1-related symptoms, and half of them died during the study. The MT-2 status of 16 patients, could be determined at the time of AIDS diagnosis; 50% were Mt-2 positive, while 50% were MT-2 negative. No difference in AIDS-defining diagnoses or CD4+ lymphocyte counts at the time of diagnosis was noted. Knowledge of the HIV-1 phenotype may improve the early recognition of progressive disease.

Entities:  

Mesh:

Year:  1994        PMID: 7908672      PMCID: PMC263037          DOI: 10.1128/jcm.32.2.364-370.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

1.  Differential ability of human immunodeficiency virus isolates to productively infect human cells.

Authors:  L A Evans; T M McHugh; D P Stites; J A Levy
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

2.  Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection.

Authors:  B Asjö; L Morfeldt-Månson; J Albert; G Biberfeld; A Karlsson; K Lidman; E M Fenyö
Journal:  Lancet       Date:  1986-09-20       Impact factor: 79.321

3.  Non-cytocidal natural variants of human immunodeficiency virus isolated from AIDS patients with neurological disorders.

Authors:  R Anand; F Siegal; C Reed; T Cheung; S Forlenza; J Moore
Journal:  Lancet       Date:  1987-08-01       Impact factor: 79.321

4.  Differences among human immunodeficiency virus strains in their capacities to induce cytolysis or persistent infection of a lymphoblastoid cell line immortalized by Epstein-Barr virus.

Authors:  K Dahl; K Martin; G Miller
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

5.  Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.

Authors:  M Tersmette; R E de Goede; B J Al; I N Winkel; R A Gruters; H T Cuypers; H G Huisman; F Miedema
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

6.  Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates.

Authors:  E M Fenyö; L Morfeldt-Månson; F Chiodi; B Lind; A von Gegerfelt; J Albert; E Olausson; B Asjö
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

7.  Biologic features of HIV-1 that correlate with virulence in the host.

Authors:  C Cheng-Mayer; D Seto; M Tateno; J A Levy
Journal:  Science       Date:  1988-04-01       Impact factor: 47.728

8.  Isolation frequency and growth properties of HIV-variants: multiple simultaneous variants in a patient demonstrated by molecular cloning.

Authors:  H von Briesen; W B Becker; K Henco; E B Helm; H R Gelderblom; H D Brede; H Rübsamen-Waigmann
Journal:  J Med Virol       Date:  1987-09       Impact factor: 2.327

9.  Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype.

Authors:  G Scarlatti; V Hodara; P Rossi; L Muggiasca; A Bucceri; J Albert; E M Fenyö
Journal:  Virology       Date:  1993-12       Impact factor: 3.616

10.  Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics.

Authors:  V A Sundqvist; J Albert; E Ohlsson; J Hinkula; E M Fenyö; B Wahren
Journal:  J Med Virol       Date:  1989-11       Impact factor: 2.327

View more
  48 in total

1.  Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization.

Authors:  A L Hammond; J Lewis; J May; J Albert; P Balfe; J A McKeating
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype.

Authors:  A Björndal; H Deng; M Jansson; J R Fiore; C Colognesi; A Karlsson; J Albert; G Scarlatti; D R Littman; E M Fenyö
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS.

Authors:  Yoshiaki Nishimura; Masashi Shingai; Wendy R Lee; Reza Sadjadpour; Olivia K Donau; Ronald Willey; Jason M Brenchley; Ranjini Iyengar; Alicia Buckler-White; Tatsuhiko Igarashi; Malcolm A Martin
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

4.  Cognitive Function Among Antiretroviral Treatment-Naive Individuals Infected With Human Immunodeficiency Virus Type 1 Subtype G Versus CRF02_AG in Nigeria.

Authors:  Jibreel Jumare; Nicaise Ndembi; Samer S El-Kamary; Laurence Magder; Laura Hungerford; Tricia Burdo; Lindsay M Eyzaguirre; Patrick Dakum; Anya Umlauf; Mariana Cherner; Alash'le Abimiku; Man Charurat; William A Blattner; Walter Royal
Journal:  Clin Infect Dis       Date:  2018-04-17       Impact factor: 9.079

5.  Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.

Authors:  H Ruppach; P Nara; I Raudonat; Z Elanjikal; H Rübsamen-Waigmann; U Dietrich
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

6.  Rapid evolution of human immunodeficiency virus strains with increased replicative capacity during the seronegative window of primary infection.

Authors:  J Ferbas; E S Daar; K Grovit-Ferbas; W J Lech; R Detels; J V Giorgi; A H Kaplan
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

7.  Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue.

Authors:  Ingrid Karlsson; Jean-Charles Grivel; Silvia Sihui Chen; Anders Karlsson; Jan Albert; Eva Maria Fenyö; Leonid B Margolis
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.

Authors:  Ulf Karlsson; Liselotte Antonsson; Johanna Repits; Patrik Medstrand; Christer Owman; Karin Kidd-Ljunggren; Lars Hagberg; Bo Svennerholm; Marianne Jansson; Magnus Gisslén; Bengt Ljungberg
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

9.  Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4.

Authors:  Gregory Q Del Prete; Beth Haggarty; George J Leslie; Andrea P O Jordan; Josephine Romano; Nathaniel Wang; Jianbin Wang; Michael C Holmes; David C Montefiori; James A Hoxie
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

10.  HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.

Authors:  John C Tilton; Heather Amrine-Madsen; John L Miamidian; Kathryn M Kitrinos; Jennifer Pfaff; James F Demarest; Neelanjana Ray; Jerry L Jeffrey; Celia C Labranche; Robert W Doms
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.